Ophthotech Announces Appointment of David E. Redlick to Its Board of Directors

January 6, 2016

Download PDF

NEW YORK–(BUSINESS WIRE)– Ophthotech Corporation (Nasdaq: OPHT) today announced the appointment of David E. Redlick to its Board of Directors effective immediately.

David Redlick recently retired as a Partner in the Corporate Practice Group at Wilmer Cutler Pickering Hale and Dorr LLP (WilmerHale), an international law firm. Mr. Redlick joined WilmerHale in 1975 and has served as the co-chair of the Life Sciences Group, the co-chair of the Corporate Department and a member of the firm’s Executive Committee. Mr. Redlick’s legal practice focused on corporate and securities law, with an emphasis on public offerings, mergers and acquisitions, venture capital transactions and corporate collaborations. For over 40 years, Mr. Redlick served as counsel for a broad range of clients, including public and private life sciences and high technology companies, investment banks, venture capital funds and real estate development and finance companies. Mr. Redlick also currently serves as a special advisor at Leerink Partners LLC, an investment bank focused exclusively on the healthcare industry.

“We welcome David to Ophthotech’s Board of Directors during this exciting time as we continue to move our product pipeline forward and prepare for data from our two ongoing Phase 3 trials of Fovista® in combination with Lucentis® for the treatment of wet age-related macular degeneration in the fourth quarter of this year,” stated David R. Guyer, M.D., Chief Executive Officer and Chairman of the Board of Ophthotech. “David’s many accomplishments and experience as a leading practitioner in the life sciences industry at an international law firm will bring valued insight to our Board as we seek to execute our plan to bring Fovista® to market as quickly as possible and advance our product pipeline.”

“This is an exciting time for Ophthotech,” stated David E. Redlick. “I am particularly pleased by the opportunity to share my experience in the life sciences with the Company. I look forward to working closely with the other Board members and supporting the Company’s management team to build sustainable shareholder value.”

About Ophthotech Corporation

Ophthotech is a biopharmaceutical company specializing in the development of novel therapeutics to treat back of the eye diseases, with a focus on developing innovative therapies for age-related macular degeneration (AMD). Ophthotech’s most advanced product candidate, Fovista® anti-PDGF therapy, is in Phase 3 clinical trials for use in combination with anti-VEGF therapy that represents the current standard of care for the treatment of wet AMD. Ophthotech’s second product candidate, Zimura®, an inhibitor of complement factor C5, is being developed for the treatment of geographic atrophy, a form of dry AMD. For more information, please visit www.ophthotech.com.

Forward-looking Statements

Any statements in this press release about Ophthotech’s future expectations, plans and prospects constitute forward-looking statements for purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995. Forward-looking statements include any statements about Ophthotech’s strategy, future operations and future expectations and plans and prospects for Ophthotech, and any other statements containing the words “anticipate,” “believe,” “estimate,” “expect,” “intend”, “goal,” “may”, “might,” “plan,” “predict,” “project,” “target,” “potential,” “will,” “would,” “could,” “should,” “continue,” and similar expressions. In this press release, Ophthotech’s forward looking statements include statements about the timing and progress of the Fovista® Phase 3 clinical program, including the timing of obtaining initial, topline data from these trials, the timing of potential marketing approval for Fovista® and the potential of Fovista® as a wet AMD combination therapy. Such forward-looking statements involve substantial risks and uncertainties that could cause Ophthotech’s clinical development programs, future results, performance or achievements to differ significantly from those expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, those related to the initiation and conduct of clinical trials, availability of data from clinical trials and expectations for regulatory approvals or other actions and other factors discussed in the “Risk Factors” section contained in the quarterly and annual reports that Ophthotech files with the SEC. Any forward-looking statements represent Ophthotech’s views only as of the date of this press release. Ophthotech anticipates that subsequent events and developments will cause its views to change. While Ophthotech may elect to update these forward-looking statements at some point in the future, Ophthotech specifically disclaims any obligation to do so except as required by law.



Ophthotech Corporation
Kathy Galante, 212-845-8231

Vice President, Investor Relations and Corporate Communications




SmithSolve LLC on behalf of Ophthotech Corporation
Jennifer Devine, 973-442-1555 ext. 102


Source: Ophthotech Corporation

News Provided by Acquire Media

Information for Patients
If you have been recently diagnosed with a retinal condition by your eye care professional, please visit the link below.
Learn More